FDA Approves IDVYNSO — Merck Sharp & Dohme LLC

# FDA Approves Merck's IDVYNSO (Doravirine/Islatravir) for HIV Treatment Merck Sharp & Dohme LLC has received FDA approval for IDVYNSO, an oral combination therapy featuring doravirine and islatravir, marking a potential competitive addition to the HIV treatment market dominated by integrase inhibitors and other antiretroviral classes. The approval could capture market share among treatment-naive and experienced HIV patients seeking alternative regimens, though its commercial impact will depend on pricing, insurance coverage, and efficacy data relative to entren